Can You Take Mounjaro While Pregnant? The Tirzepatide Diabetes Indication and Pregnancy Pathway

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 13 sources cited

Key Takeaways

• Mounjaro is not recommended in pregnancy. Discontinue when pregnancy is recognized.
• Mounjaro is tirzepatide for type 2 diabetes; Zepbound is tirzepatide for chronic weight management. Same drug, different indication.
• For pregnant patients with type 2 diabetes who had been on Mounjaro, the standard transition is to insulin.
• Lilly recommends pre-pregnancy discontinuation at least 1 month before planned conception.
• Mounjaro reduces oral contraceptive effectiveness; non-oral contraception or a barrier method is recommended for 4 weeks after initiation and after each dose escalation.

Direct answer

Mounjaro is not recommended in pregnancy. The FDA label directs discontinuation when pregnancy is recognized. The transition for pregnant patients with type 2 diabetes is typically to insulin, with tighter glycemic targets and closer obstetric coordination. If you are pregnant, planning pregnancy, or breastfeeding, do not start, continue, or stop GLP-1 or GLP-1/GIP medications without OB-GYN sign-off.

Table of contents

1. What the Mounjaro label says about pregnancy
2. How Mounjaro differs from Zepbound (and why it matters)
3. Animal reproductive data: shared between Mounjaro and Zepbound
4. Transitioning diabetes care during pregnancy
5. Glycemic targets in pregnancy
6. The oral contraceptive interaction
7. Pre-pregnancy discontinuation planning
8. If you become pregnant on Mounjaro
9. Postpartum and breastfeeding
10. The contrary view: should diabetes management ever continue?
11. FAQ
12. Sources

What the Mounjaro label says about pregnancy

The Mounjaro prescribing information includes the same Section 8.1 language as Zepbound. There are limited data on tirzepatide use in pregnant women, animal reproduction studies showed potential risk, and the label directs discontinuation when pregnancy is recognized. The label also recommends that women of reproductive potential be counseled about contraception.

Unlike Zepbound's contraindication-tier language, Mounjaro uses precaution-tier language. The reason: type 2 diabetes is a clinical condition that can continue requiring management during pregnancy, so the label preserves clinical judgment about transition timing.

How Mounjaro differs from Zepbound (and why it matters)

Mounjaro and Zepbound are tirzepatide. The molecule is the same; the FDA approvals differ:

	Mounjaro	Zepbound
Indication	Type 2 diabetes	Chronic weight management
Max dose	15 mg weekly	15 mg weekly
Pregnancy label tier	Use in specific populations (precaution)	Use in specific populations (precaution); also indication-specific framing
Underlying condition requiring continued management in pregnancy	Yes (diabetes; switch to insulin)	No (weight loss not pursued in pregnancy)

The indication difference matters less for the drug-on-fetus question and more for what happens to the patient's care after discontinuation. Diabetes requires ongoing pharmacotherapy in pregnancy for most patients; obesity does not.

Animal reproductive data: shared between Mounjaro and Zepbound

The animal data are the same as for Zepbound because the drug is the same. Rat studies showed decreased fetal body weights and structural abnormalities at exposures comparable to or below the MRHD. Rabbit studies showed decreased fetal body weights and structural abnormalities at clinically relevant exposures.

These findings flag the same biological concerns regardless of which indication the patient was treated for.

Transitioning diabetes care during pregnancy

For pregnant patients with type 2 diabetes who had been on Mounjaro, the typical transition path:

• Insulin. The preferred pharmacologic agent. Multiple regimens (basal-bolus, premixed, pump) accommodate patient lifestyles.
• Metformin. Used in some settings, often combined with insulin. Crosses the placenta.
• Glyburide. Used in some gestational diabetes settings; less commonly in pregestational type 2.

The transition includes:

• Frequent glucose monitoring during the changeover period.
• Insulin dose titration based on glucose patterns.
• Diabetes education on insulin technique if the patient was not previously on insulin.
• Coordination between the endocrinologist or primary care prescriber, the obstetric team, and (often) a certified diabetes care specialist.

Glycemic targets in pregnancy

Glycemic targets tighten in pregnancy. The American Diabetes Association Standards of Care recommend:

• Fasting glucose less than 95 mg/dL.
• 1-hour postprandial less than 140 mg/dL OR 2-hour postprandial less than 120 mg/dL.
• A1c less than 6.5 percent (or as close as possible without significant hypoglycemia).

Achieving these targets often requires more frequent monitoring than non-pregnant care, sometimes with continuous glucose monitoring. Hypoglycemia risk is higher because targets are tighter.

The oral contraceptive interaction

Tirzepatide delays gastric emptying and can reduce the absorption of orally administered medications. The Mounjaro label includes a specific warning that oral contraceptives may be less effective in patients using Mounjaro. Recommendations:

• Switch to a non-oral contraceptive method (IUD, implant, depot injection).
• OR add a barrier method for 4 weeks after starting Mounjaro and for 4 weeks after each dose escalation.

This interaction matters specifically because patients with type 2 diabetes on Mounjaro often have weight changes that can affect contraceptive efficacy independent of pharmacokinetic interactions. Layered protection is the safer default.

Pre-pregnancy discontinuation planning

Pre-conception planning for Mounjaro patients includes:

• Discontinuation at least 1 month before active conception attempts.
• Transition to a pregnancy-appropriate diabetes regimen, ideally before conception.
• Achieving target A1c before conception (typically less than 6.5 percent or as close as possible without hypoglycemia).
• Folic acid supplementation at least 1 month before conception.
• Treatment of obesity-related conditions if applicable.
• Pre-pregnancy visit with an obstetric provider, often maternal-fetal medicine for patients with pre-existing diabetes.

If you become pregnant on Mounjaro

1. Stop the medication. Do not take additional doses.
2. Contact your prescriber and OB-GYN within the day.
3. Plan an immediate diabetes care transition, typically to insulin.
4. Begin a prenatal vitamin with at least 400 mcg folic acid.
5. Schedule a dating ultrasound and standard pregnancy intake labs (including A1c).
6. Consider maternal-fetal medicine consultation for diabetes-and-medication-exposure counseling.
7. Plan a detailed anatomy ultrasound at 18 to 22 weeks.
8. Consider enrolling in the Lilly tirzepatide pregnancy exposure registry.

Postpartum and breastfeeding

LactMed advises against tirzepatide during breastfeeding until more data are available. Patients who plan to breastfeed exclusively typically defer restart. Patients who are not breastfeeding can restart after discussion with their prescriber.

Postpartum diabetes care often shifts again, because pregnancy-related insulin resistance resolves. Insulin doses typically decrease substantially in the first weeks postpartum, with risk of hypoglycemia if not adjusted.

The contrary view: should diabetes management ever continue?

The most challenging clinical scenario: a patient with poorly controlled type 2 diabetes for whom alternative agents have been inadequate, who becomes pregnant. Some endocrinologists argue that the maternal-fetal risks of poorly controlled diabetes (which include congenital malformations from hyperglycemia in early pregnancy) may exceed the theoretical risks of continued tirzepatide use until insulin is established.

This view is a minority position. The standard of care is rapid transition to insulin even if it takes weeks to establish optimal control. Insulin has decades of pregnancy safety data; tirzepatide does not.

A nuanced version of the contrary view: do not stop Mounjaro abruptly without a glucose plan. The transition window matters. Coordinate the discontinuation with insulin initiation to avoid a period of dangerously high glucose.

What to verify before using this answer

The useful next step for Can You Take Mounjaro While Pregnant? The Tirzepatide Diabetes Indication and Pregnancy Pathway is to verify the details that can change the decision: current labeling, insurance rules, pharmacy instructions, dose timing, contraindications, and whether the evidence applies to your diagnosis rather than only to weight loss headlines.

For this women's health page, the most relevant search terms are can, you, take, mounjaro, while, pregnant. Those terms point to a practical decision, so the answer should be checked against a current prescription label, payer policy, trial result, or clinician recommendation before you act.

FormBlends keeps this page focused on patient-level decision points: what is known, what is uncertain, what should be handled by a licensed clinician, and what should be avoided because it creates dosing, safety, or access risk.

FAQ

Can you take Mounjaro while pregnant? No. Discontinue when pregnancy is recognized.

Is Mounjaro the same as Zepbound? Same drug, different FDA indication.

What do I switch to for diabetes during pregnancy? Insulin, sometimes with metformin. Glyburide in select gestational diabetes settings.

How long before pregnancy should I stop Mounjaro? At least 1 month.

What did the animal studies show for tirzepatide? Decreased fetal body weights and structural abnormalities in rats and rabbits at clinically relevant exposures.

Does Mounjaro affect oral contraceptives? Yes. Use a non-oral method or add a barrier for 4 weeks after start and after each dose escalation.

What if I become pregnant on Mounjaro? Stop, call your prescriber and OB-GYN, transition diabetes care, begin prenatal vitamins.

Can I use Mounjaro for gestational diabetes? No. Insulin is standard.

Will pregnancy worsen my diabetes after stopping Mounjaro? Pregnancy increases insulin resistance; patients often need more insulin than before pregnancy.

Is breastfeeding compatible with Mounjaro? LactMed advises against use during nursing.

Related guides

• Can You Take Wegovy While Pregnant? Why the Obesity Indication Changes the Conversation
• Can You Take Zepbound While Pregnant? Tirzepatide-Specific Considerations and Pre-Conception Planning
• Can You Take Ozempic While Pregnant? What the FDA Label, Animal Studies, and ACOG Actually Say
• What Happens If You Get Pregnant on Ozempic? The Clinical Pathway From Discovery to Delivery
• Can You Take Ozempic While Breastfeeding? The LactMed Position, Manufacturer Guidance, and What Clinicians Actually Do
• Can You Take Peptides While Breastfeeding?

Sources

1. FDA. Mounjaro (tirzepatide) injection prescribing information. Warnings and Precautions, Use in Specific Populations.
2. FDA. Zepbound (tirzepatide) injection prescribing information.
3. American Diabetes Association. Standards of Care in Diabetes: Management of Diabetes in Pregnancy. Most recent edition.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
5. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
6. American College of Obstetricians and Gynecologists. Practice Bulletin 230: Obesity in Pregnancy. 2021.
7. Eli Lilly. Tirzepatide Pregnancy Exposure Registry. Manufacturer pharmacovigilance.
8. National Library of Medicine. LactMed. Tirzepatide entry.
9. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. JCEM. 2015 with updates through 2024.
10. European Medicines Agency. Mounjaro Summary of Product Characteristics. Section 4.6.
11. Society for Maternal-Fetal Medicine. Consult Series on Pregestational Diabetes.
12. ACOG Committee Opinion on Pregestational Diabetes Mellitus.
13. Wexler DJ et al. Type 2 Diabetes and Pregnancy. NEJM review article.

Footer disclaimers

Platform Disclaimer. FormBlends connects patients with independent licensed clinicians and U.S.-based pharmacies. We do not provide clinical care directly. Pregnancy and diabetes management decisions belong to you and your clinicians.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved. It is prepared by a state-licensed 503A compounding pharmacy in response to an individual prescription. Pregnancy precautions described for FDA-approved Mounjaro and Zepbound apply with at least equal weight to compounded versions.

Results Disclaimer. Diabetes outcomes during pregnancy depend on glycemic control, comorbidities, and the obstetric care plan. This article describes general clinical context, not personalized care.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.